Complete abstract information will be provided to the CMSC Annual Meeting attendees on May 28, 2023.
Year | ID | Type | Category | Title | Authors |
---|
2023 | IMG13 | Poster | Imaging |
Variability in Clinical Decision Making for Neurologists Interpreting MS MRI Brain Reports |
Lynden Bajus, BS1, Kelly Leyden, MRes1 and Cristina Granziera, MD, PhD2, (1)Octave, Menlo Park, CA, (2)Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, Faculty of Medicine, University Hospital Basel and University of Basel, Basel, Switzerland |
2023 | IMG14 | Poster | Imaging |
Cautions in Anisotropy: Thick Slices and Slice Gaps in 2D MR Acquisition Tarnish Volumetrics |
Samuel W Remedios, BS1,2, Blake E Dewey, PhD3, Yuan Xue, PhD4, Lianrui Zuo, MSE4,5, Sandra D Cassard, ScD3, Carolyn Koch, MA3, Ann Fishman, MBA6, Jerry L Prince, PhD4, Ellen M. Mowry, MD, MCR3 and Scott D Newsome, DO, MSCS3, (1)Computer Science, Johns Hopkins University, Baltimore, MD, (2)Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, (3)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (4)Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, (5)National Institute on Aging, National Institutes of Health, Baltimore, MD, (6)Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University School of Medicine, Baltimore, MD |
2023 | IMG15 | Poster | Imaging |
Quantifying Contrast Differences Among MR Images Used in Clinical Studies |
Savannah P Hays, BS1, Lianrui Zuo, MSE1,2, Blake E Dewey, PhD3, Samuel W Remedios, BS4,5, Yuan Xue, PhD1, Sandra D Cassard, ScD3, Carolyn Koch, MA3, Ann Fishman, MBA6, Aaron Carass, MS1, Peter A Calabresi, MD3, Jerry L Prince, PhD1, Ellen M. Mowry, MD, MCR3 and Scott D Newsome, DO, MSCS3, (1)Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, (2)National Institute on Aging, National Institutes of Health, Baltimore, MD, (3)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (4)Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, (5)Computer Science, Johns Hopkins University, Baltimore, MD, (6)Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University School of Medicine, Baltimore, MD |
2023 | IMG16 | Poster | Imaging |
The Relationship between Protxx Wearable Sensor Data and White Matter Microstructure in People with Multiple Sclerosis |
Sepideh Heydari, PhD1,2, Colleen Lacey, M.Sc.1, Kathryn Stewart-Good, RA1, Chantel Mayo, PhD3, John Ralston, PhD4 and Jodie R Gawryluk, Ph.D., R.Psych.1,2, (1)Psychology, University of Victoria, Victoria, BC, Canada, (2)Institute on Aging and Lifelong Health, Victoria, BC, Canada, (3)Neuropsychology, University of Manitoba, Winnipeg, MB, Canada, (4)Neursantys, Menlo Park, CA |
2023 | IMG17 | Poster | Imaging |
Retinal Layer Thickness Comparison between the UK Biobank and a Multiple Sclerosis Dataset |
Shuwen Wei, PhD1, Ji Hee Kim, PhD1, Yihao Liu, MSE1, Lianrui Zuo, MSE1,2, Shiv Saidha, MBBCh, MD, MRCPI3, Kathryn C. Fitzgerald, ScD3, Peter A Calabresi, MD3, Jerry L Prince, PhD1 and Aaron Carass, MS1, (1)Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, (2)National Institute on Aging, National Institutes of Health, Baltimore, MD, (3)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD |
2023 | IMG18 | Poster | Imaging |
Synthesizing Missing MRI Sequences to Improve Processing Images in Multiple Sclerosis |
Yuan Xue, PhD1, Blake E Dewey, PhD2, Lianrui Zuo, MSE1,3, Samuel W Remedios, BS4,5, Savannah P Hays, BS1, Sandra D Cassard, ScD2, Carolyn Koch, MA2, Ann Fishman, MBA6, Aaron Carass, MS1, Peter A Calabresi, MD2, Jerry L Prince, PhD1, Ellen M. Mowry, MD, MCR2 and Scott D Newsome, DO, MSCS2, (1)Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, (2)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (3)National Institute on Aging, National Institutes of Health, Baltimore, MD, (4)Computer Science, Johns Hopkins University, Baltimore, MD, (5)Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, (6)Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University School of Medicine, Baltimore, MD |
2023 | IMG19 | Poster | Imaging |
Clinical and Radiologic Characteristics of Early Onset and Late Onset Adult Multiple Sclerosis |
Murali Palathinkara, BS1, Abrahim N Razzak, BS1, Delaney Cairns, BS2 and Ahmed Z Obeidat, MD, Ph.D.1, (1)Neurology, Medical College of Wisconsin, Milwaukee, WI, (2)Medical College of Wisconsin, Milwaukee, WI |
2023 | LB01 | Poster | Complementary and alternative therapies |
Reduced Objective Disability in Relapsing-Remitting Multiple Sclerosis during a Dietary Intervention Trial: A Secondary Analysis of the Waves Trial |
Landon J Crippes, BS1;Solange M Saxby, PhD, RDN2;Farnoosh Shemirani, PhD2;Linda M Rubenstein, PhD3;Patrick Ten Eyck, PhD4;Lucas J Carr, PhD5;Warren G Darling, PhD5;Karin F. Hoth, PhD6;John A Kamholz, MD, PhD7;Linda G Snetselaar, PhD, RDN3;Tyler J Titcomb, PhD, RDN2 and Terry L Wahls, MD*2, (1)Carver College of Medicine, The University of Iowa, Iowa City, IA, (2)Internal Medicine, University of Iowa, Iowa City, IA, (3)Epidemiology, University of Iowa, Iowa City, IA, (4)Institute for Clinical and Translational Science, University of Iowa, Iowa City, IA, (5)Department of Health and Human Physiology, University of Iowa, Iowa City, IA, (6)Department of Psychiatry, University of Iowa, Iowa City, IA, (7)Neurology, University of Iowa, Iowa City, IA |
2023 | LB02 | Poster | Disease-modifying therapy |
Frexalimab, a CD40L Inhibitor, in Relapsing Multiple Sclerosis: Results from a Randomized Controlled Phase 2 Trial |
Patrick Vermersch, MD, PhD1;Cristina Granziera, MD, PhD2,3;Yang Mao-Draayer, MD, PhD4;Gary Cutter, MS, PhD5;Oleksandr Kalbus, MD, PhD6;Ivan Staikov, MD, PhD7;Michal Dufek, PhD8;Stephane Saubadu, MD9;Raphael Bejuit, MD9;Philippe Truffinet, MD9;Erik Wallstroem, MD, PhD10 and Gavin Giovannoni, MD, PhD, FCP, FRCP, FRCPath*11, (1)Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France, (2)Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, Faculty of Medicine, University Hospital Basel and University of Basel, Basel, Switzerland, (3)Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland, (4)Department of Neurology, Autoimmunity Center of Excellence, University of Michigan Medical Center, Michigan, MI, (5)Department of Biostatistics, UAB School of Public Health, Birmingham, AL, (6)Department of Neurology, Dnipro State Medical University, Dnipro, Ukraine, (7)Clinic of Neurology and Sleep Medicine, Acibadem City Clinic University Hospital Tokuda, Sofia, Bulgaria, (8)1st Department of Neurology, St. Anne’s University Hospital, Brno, Czech Republic, (9)Sanofi, Chilly-Mazarin, France, (10)Sanofi, Cambridge, MA, (11)Queen Mary University of London, London, United Kingdom |
2023 | LB03 | Poster | Internet and information services |
Clinical Simulation As a Novel Approach to Evaluate Digital Health Solutions: Floodlight MS Case Study |
Jack Halligan, MB BCh BAO LRCP&SI, MBA*1;Luca Capezzuto, PhD2;Simon Dryden, PhD1;Saira Ghafur, Dr, MBChB, MRCP (resp), MSc1;Stanislas Hubeaux, MSc2;Agne Kazlauskaite, PhD2 and Riley Bove, MD3, (1)Prova Health, London, United Kingdom, (2)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (3)UCSF Weill Institute for Neurosciences, San Francisco, CA |
2023 | LB04 | Poster | Neuropathology and pathogenesis |
Systematic Review of Peripheral Nervous System Involvement in Multiple Sclerosis |
Shitiz Sriwastava, MD*, UTHealth, Houston, TX;Suban Amatya, MBBS, Patan academy health science, Kathmandu, Nepal and Rajesh Gupta, MD, University of Texas at Houston, Houston, TX |
2023 | LB05 | Poster | Disease-modifying therapy |
Lymphocyte Dynamics in Patients Who Were Treated with Dimethyl Fumarate for at Least 1 Year and Subsequently Switched to Diroximel Fumarate |
Shauna M Gales, PA-C*1;Ahmed Z Obeidat, MD, PhD2;Andreina Neall, ARNP3;Kermit A Lloyd, MD4;Nicholas Belviso, PhD5;Seth Levin, MD5;Ivan Bozin, MD6;Jason P. Mendoza, PhD5;James B. Lewin, PharmD5 and Michael D Kornberg, MD PhD MS7, (1)Mellen Center, Cleveland Clinic Foundation, Cleveland, OH, (2)Neurology, Medical College of Wisconsin, Milwaukee, WI, (3)Orlando Health, Orlando, FL, (4)Riverside Neurology Specialists, Newport News, VA, (5)Biogen, Cambridge, MA, (6)Biogen, Baar, Switzerland, (7)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD |
2023 | LB06 | Poster | Quality of life and outcomes |
Patient-Reported Health Inequities Among Multiple Sclerosis Patients |
Beth Schneider, BA*, Research, MyHealthTeam, San Francisco, CA;Chris Hardy, MS, Research, Publicis Health Media, New York, NY and Elizabeth Luce, BS, MBA, MyHealthTeam, San Francisco, CA |
2023 | LB07 | Poster | Disease-modifying therapy |
Disease-Modifying Therapies, Outcomes, Risk Factors and Severity of COVID-19 in Multiple Sclerosis: A Menactrims Registry Based Study |
Maya Zeineddine, PharmD, PHD Candidate*, Neurology Institute, Harley Street Medical Center, Abu Dhabi, United Arab Emirates; Institute of Epidemiology and Tropical Neurology, Limoges University, Limoges, France and Bassem Yamout, MD, American University of Beirut Medical Center, Beirut, Lebanon |
2023 | LB08 | Poster | Neurophysiology; Neuropsychology and neuropsychiatry |
Excitatory-Inhibitory Cortical (Im)Balance Predicts Disability in Multiple Sclerosis: A Transcranial Magnetic Stimulation Study |
Arthur R. Chaves, PhD*, Health Sciences, University of Ottawa, Ottawa, ON, Canada;Sara Tremblay, PhD, Départment de psychoéducation et psychologie, Université du Québec en Outaouais, Gatineau, QC, Canada;Lara A. Pilutti, PhD, Brain and Mind Research Institute, University of Ottawa, Ottawa, ON, Canada;Michelle Ploughman, PhD, Physical Medicine & Rehabilitation, Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NF, Canada and CEPL, Recovery and Performance Lab, and NEST Lab |
2023 | LB09 | Poster | Disease-modifying therapy |
Real-World Satisfaction and Experience with Injection and Autoinjector Device for Ofatumumab Indicated for Multiple Sclerosis |
Amy Perrin Ross, APN, MSN, CNRN, MSCN*1;Jacqueline Nicholas, MD, MPH2;Ming-Hui Tai, PhD3;Stephen Yeung, MD3;Nazneen Fatima Shaikh, PhD4;Helen Chen, BS4;Mariana Fernandes, MS4 and Kevin Hawkins, PhD4, (1)Neuroscience Nurse Consultant, Oak Brook, IL, (2)OhioHealth Multiple Sclerosis Center, 3535 Olentangy River Rd, Suite 1501, Columbus, OH, (3)Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, (4)Real World Solutions, IQVIA, 2400 Ellis Road Durham, NC |
2023 | LB10 | Poster | Disease-modifying therapy |
Ofatumumab Effectiveness and Safety in Relapsing Multiple Sclerosis Patients with Breakthrough Disease on Oral Fumarates or Fingolimod: Artios Interim Analysis |
Riley Bove, MD*1;Matthew Craner, MB ChB FRCP PhD2;Dawn Langdon, PhD3;Daniel Sienkiewicz, PhD4;Javier Ricart, PhD5;Soudeh Ansari, PhD6;Sophie Arnould, MSc7;Ibolya Boer, MD7 and Tobias Derfuss, MD8, (1)University of California San Francisco, San Francisco, CA, (2)John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, (3)Royal Holloway, University of London, London, United Kingdom, (4)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (5)Novartis Farmacéutica, Barcelona, Spain, (6)Novartis Institutes for Biomedical Research, Cambridge, MA, (7)Novartis Pharma AG, Basel, Switzerland, (8)Neurology Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine and Biomedicine, University Hospital and University of Basel, Basel, Switzerland |
2023 | LB11 | Poster | Disease-modifying therapy |
Real-World Outcomes and Treatments for Natalizumab-Associated Progressive Multifocal Leukoencephalopathy |
Dusan Stefoski, MD1;John Foley, MD*2;Cortnee Roman, MSN, FNP-BC2;Karen Smirnakis, MPH3;Kerry McCarthy, BSN3;Robin L. Avila, PhD3;Thuy Luu, MD3;Aaron Galluzzi, PhD4;Liesel Dsilva, PhD3 and Jennifer Lyons, MD3, (1)Rush Medical College, Chicago, IL, (2)Rocky Mountain MS Clinic, Salt Lake City, UT, (3)Biogen, Cambridge, MA, (4)Cytel, Cambridge, MA |
2023 | LB12 | Poster | Quality of life and outcomes |
Multiple Sclerosis: Importance of Patient-Centric Education on Healthcare Communications and Decisions |
Elaine Rudell, CHCP1;Michele F. Ingram, BS1;Alicia Zambri, NA1;Tarjani Agrawal, PhD1;Olga Syritsyna, MD2;Nancy McLinskey, MD2;Patricia Melville, ANP-BC, MSCN3;Brant Oliver, PhD, MS, MPH, APRN-BC, MSCN4 and Patricia K. Coyle, MD*2, (1)Projects In Knowledge Powered by Kaplan, Short Hills, NJ, (2)MS Comprehensive Care Center, Stony Brook Neurosciences Institute, Stony Brook, NY, (3)Dept. of Neurology, MS Comprehensive Care Center, SUNY at Stony Brook, Stony Brook, NY, (4)Chronic Health Improvement Research Program at Dartmouth Health, Hanover, NH |
2023 | LB13 | Poster | Case Reports/Case Series |
Consultative, Proactive Physical Therapy in Early Multiple Sclerosis |
Monica Hendricksen, PT, DPT1;Jake Boyer, PT, DPT1;Kristen Hohl, PT, DPT, NCS1;Edith Graham, MD2;Roumen Balabanov, MD3;Miriam Rafferty, DPT, PhD1 and Dominique Kinnett-Hopkins, PhD*4, (1)Shirley Ryan AbilityLab, Chicago, IL, (2)Northwestern University, Chicago, IL, (3)Rush University Multiple Sclerosis Center, Chicago, IL, (4)School of Kinesiology, University of Michigan, Ann Arbor, MI |
2023 | LB14 | Poster | Disease-modifying therapy |
SARS-CoV-2 Vaccine Response in RMS Patients Treated with Ozanimod and Other DMTs: 48-Weeks Results from the Z-CAN Trial |
Daniel Kantor, MD*, Center for Global Health, University of Pennsylvania, Philadelphia, PA |
2023 | LB15 | Poster | Disease-modifying therapy |
Real-World Persistence of Ofatumumab Vs. Oral Disease Modifying Therapies in Patients with Multiple Sclerosis |
Magdaliz Gorritz, MPH1;Chi-Chang Chen, PhD1;Rifat Tuly, MPH1;Yifan Gu, MS1;Abhijit Gadkari, PhD2;Brandon Brown, PharmD2;Qiujun Shao, PhD2 and Carrie M Hersh, DO, MS, FAAN*3, (1)IQVIA, Plymouth Meeting, PA, (2)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (3)Mellen Program for Multiple Sclerosis Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV |
2023 | LB16 | Poster | Disease-modifying therapy |
Cladribine Tablets after Treatment with Natalizumab (CLADRINA) Trial – Clinical Analysis |
Peter Sguigna, MD*1;Annette F Okai, MD2;Jeffrey Kaplan, MD3;Kyle Blackburn, MD1;Lauren Tardo, MD1;Lori A Lebson, PhD4;Julie Korich, PhD4;Navid Manouchehri, MD1;Rehana Z Hussain, MSc1 and Olaf Stuve, MD, PhD5, (1)University of Texas Southwestern Medical Center, Dallas, TX, (2)North Texas Institute of Neurology & Headache, Plano, TX, (3)Kansas City Multiple Sclerosis and Headache Center, Overland Park, KS, (4)EMD Serono, Rockland, MA, (5)Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX |
2023 | MDC01 | Poster | Multidisciplinary care |
An Innovative Multidisciplinary Approach to Fatigue Management Utilizing the Shared Medical Appointment Model |
Alexa Kane, PsyD, The Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH |
2023 | MDC02 | Poster | Multidisciplinary care |
A Tale of Two Clinics: Providing Targeted and Efficient Spasticity Management and Virtual Neurology Care for People with Advanced Multiple Sclerosis |
Alexander Burnham, MS, CCC-SLP, MSCS1, Stephen Koelbel, MD2, Maria K Houtchens, MD3, Jonathan Zurawski, MD4, Kristy Ford, MS, OTR/L5, Lynn Stazzone, NP6 and John M. Sullivan, PA-C4, (1)Rehabilitation Services, The Boston Home, Boston, MA, (2)Spasticity Management, The Boston Home, Boston, MA, (3)Neurology, Brigham Multiple Sclerosis Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, (4)Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Boston, MA, (5)Admissions, The Boston Home, Boston, MA, (6)Brigham and Women’s Hospital, Boston, MA |
2023 | MDC03W | Poster | Multidisciplinary care |
Prescription for Wellness: Pilot Study for MS Patients to Improve Metabolic Profile and MS Quality of Life Parameters |
Asya Wallach, MD1, Reg Grant, CAT(C), CSCS, RSCC*E2, Jeffrey Portnoy, PhD2, Gautam Bhasin, PsyD2, Thomas Birch, MD2, Brianne Etter, PT, DPT, CLT2, Deborah Bessen, RD2, Tracee Yablon Brenner, RD2, Matthew Hoeppner, PA-C2, Jason Kavountzis, PT, MAS, OCS2, Maxwell Edmiston, MSA, CSCS2 and Mary Ann Picone, MD1, (1)Holy Name MS Center, Teaneck, NJ, (2)Holy Name, Teaneck, NJ |
2023 | MDC05 | Poster | Multidisciplinary care |
Using a Standardized Quality Improvement Process to Incorporate Patient-Reported Symptom Data in Routine Clinical Care |
Deborah M Miller, PhD, LISW1, Benjamin M Pannell, MS2, Nichole Davis, BA3, Alexa Kane, PsyD4, Desiree Chizmadia, MSN5, Hilary Young, PA-C5, Deja Rose, M.D.6, Kasandra Weigland, BA7, Stephanie Covert, DPT8 and Robert A. Bermel, MD9, (1)Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH, (2)NA, Cleveland, OH, (3)OR, Cleveland Clinic, Cleveland, OH, (4)The Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, (5)Mellen Center, Cleveland Clinic, Cleveland, OH, (6)Neurology, Emory University, Atlanta, GA, (7)Workforce Strategies Administration, Cleveland Clinic, Cleveland, OH, (8)Neurological Institute, Cleveland Clinic, Cleveland, OH, (9)Mellen Center for MS, Department of Neurology, Cleveland Clinic, Cleveland, OH |
2023 | MDC06 | Poster | Multidisciplinary care |
Implementing a Community-Based Virtual Tool to Characterize Sidewalk Accessibility in a Northern New Jersey (NJ) Town |
Kie Fujii, BA1,2, Katrina Ma, N/A3, Chu Li, MS3, Michael Saugstad, N/A3, Lisa Stolarz, MA2, Michael I Starr, MBA2, Florian P Thomas, MD, PhD1,2,4 and Jon Froehlich, PhD3, (1)Department of Neurology, Hackensack Meridian School of Medicine, Nutley, NJ, (2)National MS Society – NJM Community Council, Bergen County, NJ, (3)Allen School of Computer Science & Engineering, University of Washington, Seattle, WA, (4)Department of Neurology & Neuroscience Instiutute, Hackensack University Medical Center, Hackensack, NJ |
2023 | MDC07W | Poster | Multidisciplinary care |
The Role of Behavioral Medicine in Inpatient Care of MS and AE |
Grace E Tworek, Psy.D., The Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH |
2023 | MDC08 | Poster | Multidisciplinary care |
Impact to Immunization Completion Rates By Incorporating Clinical Pharmacists on a Multiple Sclerosis Care Team |
Nicole Hahn, PharmD, BCACP1, Shilpa Klocke, PharmD, BCPS1, Thomas Delate, PhD, MS2 and Samuel Cohn, MD1, (1)Neurology, Kaiser Permanente Colorado, Denver, CO, (2)National Pharmacy Services, Kaiser Permanente, Aurora, CO |
2023 | MDC09 | Poster | Multidisciplinary care |
Patterns of Multiple Sclerosis Presentation to the Emergency Department |
Alaa Maglan, MBBS1, Osama Khojah, MBBS2, Faris Allaf, MBBS3, Saeed Alamoudi, MBBS4, Meral Altayeb, MBBS3, Rawaf Alsharif, MBBS3, Mohamed Eldigire Ahmed, MBBS5 and Seraj Makkawi, MBBS3, (1)College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia, (2)Department of Medicine, Ministry of the National Guard-Health Affairs, Jeddah, Saudi Arabia, (3)King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia, (4)King Khalid Eye Specialist Hospital, Jeddah, Saudi Arabia, (5)King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia |
2023 | MOC02 | Poster | Methods of Care |
Seropositive Mog Antibody-Associated Syndrome That Presented As Clippers-like Brainstem Syndrome, a Case Presentation and Literature Review |
Eric Yeager, MD, Neurology, UT Health San Antonio, San Antonio, TX, Xavier Carrier, MD, Radiology, UT Health San Antonio, san antonio, TX, Mathew Roberts, MD, Neurology, UT Health San Antonio, san antonio, TX and Tania Reyna, MD, Neurology, University of Texas Health San Antonio, San Antonio, TX |
2023 | MOC03 | Poster | Methods of Care |
Combined Central and Peripheral Demyelination: Clinical and Immunologic Aspects |
Ganiru O Anunike, BA, Vikhyathi Pallerla, BS, MSBS, Boyd M Koffman, M.D., Ph.D and Sabeena I Malik, MD, Neurology, University of Toledo College of Medicine and Life Sciences, Toledo, OH |
2023 | MOC04 | Poster | Methods of Care |
Detection of Silent UTI – a Case Study |
Heather Hua, RN, MSN, MSCN1, Danielle Siniscalchi, MBA1, Deanna Power, RN, MSCN1 and Jennifer Graves, MD, PhD, MAS2, (1)Octave, Menlo Park, CA, (2)University of California San Diego, San Diego, CA |
2023 | MOC05 | Poster | Methods of Care |
Trigeminal Neuralgia in Multiple Sclerosis: Association with Demyelination and Progression |
Hossein Mousavi, MD1, John W. Lindsey, MD2, Rajesh Gupta, MD3, Jerry S. Wolinsky, MD4 and John A Lincoln, MD3, (1)Neurology, University of Texas Health Center at Houston, Houston, TX, (2)Multiple Sclerosis And Neuroimmunology, McGovern Medical School, Houston, TX, (3)University of Texas at Houston, Houston, TX, (4)Test Department, Test Affiliation, Hackensack, NJ |
2023 | MOC06 | Poster | Methods of Care |
Subcutaneous Granulomata and Calcifications Secondary to Interferon-Beta-1a Injections Decades Prior in a Patient with Multiple Sclerosis: A Case Report and Literature Review |
Mara Bahri, MSc, The Ohio State University College of Medicine, Columbus, OH and Kristi Epstein, APRN-CNP, Department of Neurology, The Ohio State University, Columbus, OH |
2023 | MOC07 | Poster | Methods of Care |
Implementing a Multidisciplinary Approach for Older Adults with Multiple Sclerosis: Development of the Aging with MS Clinic |
Mara Bahri, MSc1, Brooke Gaul, PT, DPT2, Claire Thieneman, PharmD3, Sarah Grim, LISW-S4, Kristi Epstein, APRN-CNP4, Rolanda Robinson, PhD4, Sarita Maturu, DO4 and Yinan Zhang, MD4, (1)The Ohio State University College of Medicine, Columbus, OH, (2)Outpatient Rehabilitation, Neurology, The Ohio State University, Columbus, OH, (3)The Ohio State University, Columbus, OH, (4)Department of Neurology, The Ohio State University, Columbus, OH |
2023 | MOC08 | Poster | Methods of Care |
The Pearls and Pitfalls of the Inpatient-Outpatient Transition in Newly Diagnosed Neuromyelitis Optica Spectrum Disorder |
Ross C Crandall, MD, Neurology Residency Program, University of Colorado School of Medicine, Aurora, CO, Aaron Carlson, MD, Neurology, University of Colorado, Anschutz Medical Campus, Denver, CO, Amanda L Piquet, MD, Neurology, University of Colorado School of Medicine, Aurora, CO and Kavita V Nair, PhD, Rocky Mountain Multiple Sclerosis Center at the University of Colorado, Aurora, CO |
2023 | MOC09 | Poster | Methods of Care |
An Unusual Case of Bilateral Optic Neuropathy and Encephalopathy |
Samantha N Roman, MD and Scott D Newsome, DO, MSCS, Neurology, Johns Hopkins University School of Medicine, Baltimore, MD |
2023 | MOC10 | Poster | Methods of Care |
Ocrelizumab-Induced Psoriasis in a Patient with Relapsing-Remitting Multiple Sclerosis |
Sara Esmaeili, Research Fellow, Neurology, University of Cincinnati, Cincinnati, OH and Aram Zabeti, MD, Waddell Center for Multiple Sclerosis, University of Cincinnati, Cincinnati, OH |
CMSC Scholar © 2020 All rights Reserved | Proudly Created by Adapting Social